The endocannabinoid system and its therapeutic implications in rheumatoid arthritis

Huan Gui, Qiang Tong, Wenchun Qu, Chen Mei Mao, Sheng Ming Dai

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Abstract Since the discovery of the endogenous receptor for Δ9-tetrahydrocannabinol, a main constituent of marijuana, the endocannabinoid system (comprising cannabinoid receptors and their endogenous ligands, as well as the enzymes involved in their metabolic processes) has been implicated as having multiple regulatory functions in many central and peripheral conditions, including rheumatoid arthritis (RA). RA is an immune-mediated inflammatory disease that is associated with the involvement of many kinds of cells (such as fibroblastlike synoviocytes [FLSs], osteoclasts, T cells, B cells, and macrophages) and molecules (such as interleukin-1β, tumor necrosis factor-α, interleukin-6, matrix metalloproteinases [MMPs], and chemokines). Increasing evidence suggests that the endocannabinoid system, especially cannabinoid receptor 2 (CB2), has an important role in the pathophysiology of RA. Many members of the endocannabinoid system are reported to inhibit synovial inflammation, hyperplasia, and cartilage destruction in RA. In particular, specific activation of CB2 may relieve RA by inhibiting not only the production of autoantibodies, proinflammatory cytokines, and MMPs, but also bone erosion, immune response mediated by T cells, and the proliferation of FLSs. In this review, we will discuss the possible functions of the endocannabinoid system in the modulation of RA, which may be a potential target for treatment.

Original languageEnglish (US)
Article number3589
Pages (from-to)86-91
Number of pages6
JournalInternational Immunopharmacology
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Endocannabinoids
Rheumatoid Arthritis
Cannabinoid Receptors
Matrix Metalloproteinases
Therapeutics
T-Lymphocytes
Dronabinol
Osteoclasts
Cannabis
Interleukin-1
Chemokines
Autoantibodies
Cartilage
Hyperplasia
Interleukin-6
B-Lymphocytes
Tumor Necrosis Factor-alpha
Macrophages
Cell Proliferation
Cytokines

Keywords

  • Cannabinoid receptors
  • Drug therapy
  • Endocannabinoid system
  • Endocannabinoids
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. / Gui, Huan; Tong, Qiang; Qu, Wenchun; Mao, Chen Mei; Dai, Sheng Ming.

In: International Immunopharmacology, Vol. 26, No. 1, 3589, 01.01.2015, p. 86-91.

Research output: Contribution to journalArticle

Gui, Huan ; Tong, Qiang ; Qu, Wenchun ; Mao, Chen Mei ; Dai, Sheng Ming. / The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. In: International Immunopharmacology. 2015 ; Vol. 26, No. 1. pp. 86-91.
@article{c14a194543ed4b789b3928a97bc91b6b,
title = "The endocannabinoid system and its therapeutic implications in rheumatoid arthritis",
abstract = "Abstract Since the discovery of the endogenous receptor for Δ9-tetrahydrocannabinol, a main constituent of marijuana, the endocannabinoid system (comprising cannabinoid receptors and their endogenous ligands, as well as the enzymes involved in their metabolic processes) has been implicated as having multiple regulatory functions in many central and peripheral conditions, including rheumatoid arthritis (RA). RA is an immune-mediated inflammatory disease that is associated with the involvement of many kinds of cells (such as fibroblastlike synoviocytes [FLSs], osteoclasts, T cells, B cells, and macrophages) and molecules (such as interleukin-1β, tumor necrosis factor-α, interleukin-6, matrix metalloproteinases [MMPs], and chemokines). Increasing evidence suggests that the endocannabinoid system, especially cannabinoid receptor 2 (CB2), has an important role in the pathophysiology of RA. Many members of the endocannabinoid system are reported to inhibit synovial inflammation, hyperplasia, and cartilage destruction in RA. In particular, specific activation of CB2 may relieve RA by inhibiting not only the production of autoantibodies, proinflammatory cytokines, and MMPs, but also bone erosion, immune response mediated by T cells, and the proliferation of FLSs. In this review, we will discuss the possible functions of the endocannabinoid system in the modulation of RA, which may be a potential target for treatment.",
keywords = "Cannabinoid receptors, Drug therapy, Endocannabinoid system, Endocannabinoids, Rheumatoid arthritis",
author = "Huan Gui and Qiang Tong and Wenchun Qu and Mao, {Chen Mei} and Dai, {Sheng Ming}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.intimp.2015.03.006",
language = "English (US)",
volume = "26",
pages = "86--91",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The endocannabinoid system and its therapeutic implications in rheumatoid arthritis

AU - Gui, Huan

AU - Tong, Qiang

AU - Qu, Wenchun

AU - Mao, Chen Mei

AU - Dai, Sheng Ming

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Abstract Since the discovery of the endogenous receptor for Δ9-tetrahydrocannabinol, a main constituent of marijuana, the endocannabinoid system (comprising cannabinoid receptors and their endogenous ligands, as well as the enzymes involved in their metabolic processes) has been implicated as having multiple regulatory functions in many central and peripheral conditions, including rheumatoid arthritis (RA). RA is an immune-mediated inflammatory disease that is associated with the involvement of many kinds of cells (such as fibroblastlike synoviocytes [FLSs], osteoclasts, T cells, B cells, and macrophages) and molecules (such as interleukin-1β, tumor necrosis factor-α, interleukin-6, matrix metalloproteinases [MMPs], and chemokines). Increasing evidence suggests that the endocannabinoid system, especially cannabinoid receptor 2 (CB2), has an important role in the pathophysiology of RA. Many members of the endocannabinoid system are reported to inhibit synovial inflammation, hyperplasia, and cartilage destruction in RA. In particular, specific activation of CB2 may relieve RA by inhibiting not only the production of autoantibodies, proinflammatory cytokines, and MMPs, but also bone erosion, immune response mediated by T cells, and the proliferation of FLSs. In this review, we will discuss the possible functions of the endocannabinoid system in the modulation of RA, which may be a potential target for treatment.

AB - Abstract Since the discovery of the endogenous receptor for Δ9-tetrahydrocannabinol, a main constituent of marijuana, the endocannabinoid system (comprising cannabinoid receptors and their endogenous ligands, as well as the enzymes involved in their metabolic processes) has been implicated as having multiple regulatory functions in many central and peripheral conditions, including rheumatoid arthritis (RA). RA is an immune-mediated inflammatory disease that is associated with the involvement of many kinds of cells (such as fibroblastlike synoviocytes [FLSs], osteoclasts, T cells, B cells, and macrophages) and molecules (such as interleukin-1β, tumor necrosis factor-α, interleukin-6, matrix metalloproteinases [MMPs], and chemokines). Increasing evidence suggests that the endocannabinoid system, especially cannabinoid receptor 2 (CB2), has an important role in the pathophysiology of RA. Many members of the endocannabinoid system are reported to inhibit synovial inflammation, hyperplasia, and cartilage destruction in RA. In particular, specific activation of CB2 may relieve RA by inhibiting not only the production of autoantibodies, proinflammatory cytokines, and MMPs, but also bone erosion, immune response mediated by T cells, and the proliferation of FLSs. In this review, we will discuss the possible functions of the endocannabinoid system in the modulation of RA, which may be a potential target for treatment.

KW - Cannabinoid receptors

KW - Drug therapy

KW - Endocannabinoid system

KW - Endocannabinoids

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84925428378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925428378&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2015.03.006

DO - 10.1016/j.intimp.2015.03.006

M3 - Article

VL - 26

SP - 86

EP - 91

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 1

M1 - 3589

ER -